Monthly Archives: August 2011

Not a day goes by that pundits aren’t bemoaning the struggles of the drug industry: R&D productivity declines, FDA uncertainties, restructurings and downsizings, payor and reimbursement dynamics, pricing pressures, generics and patent cliffs, etc…   Many critics worry about  slowing growth

Our friends at HBM Partners just published their quarterly Biotech/Pharma M&A report.  Its got some good nuggets of data in it about 1H2011. Although its hard to think about in the midst of the Great August Rollercoaster in the markets,

A few weeks ago I wrote a pair of blogs comparing Tech vs Life Science venture capital backed investments: one was on returns in the 2000′s where LS beat out Tech investing (highlighting a Nature Biotech article Bijan Salehizadeh of Highland Capital